Shares of Kura Oncology Inc (NASDAQ:KURA) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $30.20.
KURA has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Tuesday, October 16th. ValuEngine lowered shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 19th. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Kura Oncology in a research report on Monday, October 22nd. Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Monday, October 22nd. Finally, BidaskClub lowered shares of Kura Oncology from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 24th.
In other news, major shareholder Ecor1 Capital Fund Qualified, acquired 40,538 shares of the business’s stock in a transaction dated Thursday, December 13th. The stock was bought at an average cost of $13.90 per share, for a total transaction of $563,478.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.30% of the stock is currently owned by company insiders.
KURA stock opened at $14.31 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76. Kura Oncology has a 12 month low of $10.20 and a 12 month high of $24.02. The company has a market capitalization of $544.31 million, a PE ratio of -9.41 and a beta of 2.97.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: Bear Market – How and Why They Occur
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.